Online inquiry

IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1118MR)

This product GTTS-WQ1118MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1118MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7840MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ10739MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ12525MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ695MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ12347MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ15926MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ1764MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ6048MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW